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Background: Rheumatoid arthritis (RA) is an autoimmune disease of which the pathogenetic mechanisms are not
fully understood. Semaphorin3A (Sema3A) has an immune regulatory role. Neuropilin1 (NRP1), the primary receptor
for Sema3A, is also a receptor for vascular endothelial growth factor 165 (VEGF165). It has been shown that Sema3A
competitively antagonizes VEGF165 signaling. This study investigated whether Sema3A is expressed in synovial
tissues, and is associated with disease activity and the histological features of synovial tissues from RA patients.
Methods: Human synovial tissues samples were obtained from RA and osteoarthritis (OA) patients. Disease activity of
RA patients was calculated using the 28-joint Disease Activity Score based on C-reactive protein (DAS28-CRP). The
histological features of RA synovial tissues were evaluated using Rooney’s inflammation scoring system. The localization
of Sema3A, VEGF165 and NRP1 positive cells was immunohistochemically determined in synovial tissues. Expression levels
of Sema3A, VEGF-A and NRP1 mRNA were determined using quantitative real-time polymerase chain reaction (qPCR).
Results: In OA specimens, Sema3A, VEGF165 and NRP1 proteins were expressed in the synovial lining and
inflammatory cells beneath the lining. Immunohistochemistry revealed the protein expression of Sema3A in
synovial lining cells was decreased in RA tissues compared with OA samples. qPCR analysis demonstrated a
significant reduction of Sema3A mRNA levels in RA synovial tissue samples than in OA and a significant
correlation of the ratio of Sema3A/VEGF-A mRNA expression levels with DAS28-CRP (R = −0.449, p = 0.013).
Sema3A mRNA levels also correlated with Rooney’s inflammation score, especially in perivascular infiltrates of
lymphocytes (R = −0.506, p = 0.004), focal aggregates of lymphocytes (R = −0.501, p = 0.005) and diffuse
infiltrates of lymphocytes (R = −0.536, p = 0.002).
Conclusions: Reduction of Sema3A expression in RA synovial tissues may contribute to pathogenesis of RA.
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Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease characterized by progressive joint destruction that ac-
companies the proliferation of synovial cells and blood
vessels as well as invasion of inflammatory cells [1-3]. Al-
though the initiating factors of RA are unknown, auto-
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reproduction in any medium, provided the orRA joints, immune cells such as T and B cells invade the
hyperplastic synovial membranes [4]. Activated synovial T
and B cells secrete various types of pro-inflammatory cyto-
kines including interleukin-1 (IL-1), IL-17 and tumor ne-
crosis factor-α (TNF-α). These cytokines induce the
synthesis of matrix degrading enzymes in chondrocytes.
Synovial fibroblasts also produce matrix-degrading enzymes
and can invade cartilage, leading to its destruction [3,4].
Semaphorins are a large family of proteins that func-
tion as guidance cues for axonal/dendritic projections.
Class 3 semaphorins are vertebrate secreted proteins
and include seven members, semaphorin3A (Sema3A) to
Semaphorin3G (Sema3G) [5]. Sema3A is a repulsiveral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and Semaphorin3F (Sema3F) repulse sympathetic nerve
fibers [6]. Whereas the primary receptor for Sema3A is
neuropilin1 (NRP1), Sema3F has a higher binding affin-
ity to neuropilin2 (NRP2). Sema3C binds to both NRP1
and NRP2 [7,8].
The action of Sema3A is not limited to the nervous
system as NRP1 is expressed on endothelial cells, kerati-
nocytes, T cells, and tumor cells in breast and prostate
cancer. Sema3A inhibits angiogenesis, migration of kera-
tinocytes, proliferation of T cells, and migration of
tumor cells [8-11]. In addition, it was recently shown
that Sema3A is involved in the entry of dendritic cells to
the lymphatic system [12]. Several studies have indicated
that a reduction of Sema3A expression is involved in the
exacerbation of autoimmune diseases, such as RA and
systemic lupus erythematosus (SLE) [13,14].
NRP1 mediates signal transduction through PlexinA co-
receptors [15], which are classified into four sub-families,
PlexinA1–4 [16]. The Sema3A/NRP1/PlexinA complex
regulates the actin cytoskeleton through small G-proteins,
including Rac and Rho [17]. In immune cells, the Rac fam-
ily is associated with the proliferation and activation of B
cells [18], and the activation of T cells induced by den-
dritic cells [19]. NRP1 is also a putative marker of regula-
tory T cells [20], and therefore Sema3A/NRP1/PlexinA
signaling may modulate regulatory T cell functions.
Vascular endothelial growth factor165 (VEGF165), a
spliced isoform of VEGF-A [21], binds to NRP1 [22].
VEGF is a key regulator of angiogenesis and is involved
in the development of inflammation [23]. In RA
patients, serum VEGF levels positively correlate with
disease activity score and joint destruction [24,25]. Be-
cause NRP1 is a common receptor for Sema3A and
VEGF165 [11,26], the efficacy of VEGF165 is attributed to
Sema3A expression. Indeed, the imbalance between
Sema3A and VEGF expression levels is also associated
with disease activity in several tumors [27-29].
These facts prompted us to investigate the possibility
that Sema3A expression and/or the balance of Sema3A
and VEGF165 expression may regulate the disease activity
of RA including inflammation, angiogenesis and prolifera-
tion of synovial cells. We found that Sema3A expression
was decreased in RA synovial tissues when compared with
osteoarthritis (OA) samples. The Sema3A expression level
was also significantly associated with the RA pathological
score and disease activity score.
Methods
Patients and samples
Synovial tissue samples were obtained from RA (n = 30)
and OA (n = 23) patients during total knee arthroplasty.
The diagnosis of patients with RA and OA was based on
the revised 1987 American Rheumatism AssociationCriteria for RA [30] and the American Rheumatism As-
sociation Criteria for OA [31], respectively, as shown in
Table 1. Before arthroplasty, the disease activity of each
RA patient was evaluated using the 28-joint Disease Ac-
tivity Score based on C-reactive protein (DAS28-CRP)
[30,32]. This study was approved by the Ethics Commit-
tee of Yokohama City University Graduate School of
Medicine, and written informed consent was obtained
from all patients involved in this study (notice of ap-
proval Institutional Review Board protocol number:
B1100513031).
Hematoxylin and eosin (HE) staining for histological
assessment
Tissue specimens were fixed with 20% formalin and
embedded in paraffin. Paraffin sections (4 μm thick)
were stained with HE. The histological features of RA
synovial tissues were evaluated using Rooney’s inflamma-
tion scoring system [33]. These histological parameters
included the degree of synovial hyperplasia, fibrosis, the
number of blood vessels, focal and diffuse aggregates of
lymphocytes and perivascular infiltrates of lymphocytes.
All parameters were scored separately on a scale of 0–10
(Table 2). Two investigators (S.T. and Y.N.) independ-
ently assessed the histologic severity.
Immunohistochemistry
For immunostaining of Sema3A, antigen retrieval was per-
formed by incubating at 95°C for 30 min in DAKO Target
Retrieval Solution (pH 9.0; DAKO, Glostrup, Denmark).
For immunostaining of NRP1, VEGF165, CD3 and CD20,
the tissue sections were subjected to antigen retrieval by
autoclaving in 10 mM citrate buffer (pH 6.0) for 15 min at
121°C. Slides were then treated with 0.3% H2O2 for 30 min
to block endogenous peroxidases. Sections for Sema3A,
NRP1 and VEGF165 staining were blocked with 10% normal
goat serum. All sections were incubated at 4°C overnight
with rabbit anti-Sema3A polyclonal antibody (1:200;
Abcam, Cambridge, UK), mouse anti-CD3 monoclonal
antibody (1:50; DAKO), mouse anti-CD20 monoclonal
antibody (DAKO), rabbit anti-NRP1 polyclonal antibody
(1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or
rabbit anti-VEGF165 polyclonal antibody (1:100; Millipore,
MA, USA). This was followed by incubation with Envi-
sion™, Rabbit/HRP (DAKO) for Sema3A, NRP1 and
VEGF165 or Envision
™/HRP (DAKO) for CD3 and CD20.
Immunoreactivity was visualized using 3,3’-diaminobenzi-
dine plus (DAB+, DAKO) for Sema3A, NRP1 and VEGF165,
or 3,3’-diaminobenzidine tetrahydrochloride (DAB; Sigma-
Aldrich, St. Louis, MO, USA) for CD3 and CD20. Finally,
the sections were counterstained with hematoxylin and
mounted. Controls for Sema3A immunohistochemistry
included preabsorption and co-incubation of the antibody
with the antigen peptide (1 μl/ml; Abcam).
Table 1 Characteristics of patients with OA and RA
OA (n = 23) RA (n = 30)
Male/female, n 2/21 6/24
Age, mean ± SD (range, years) 76.6 ± 5.8 (64–84) 69.4 ± 8.1 (55–83)
Disease duration, mean ± SD (years) 10.7 ± 5.1 16.3 ± 9.1
CRP, mean ± SD (mg/dl) 0.16 ± 0.30 1.43 ± 1.21
DAS28-CRP, mean ± SD – 3.74 ± 0.84
Medications
Prednisolone, n (%) NA 17 (56.7)
Methotrexate, n (%) NA 15 (50.0)
Sulfasalazine, n (%) NA 7 (23.3)
Bucillamine, n (%) NA 6 (20.0)
Cyclosporine, n (%) NA 3 (10.0)
Actarit, n (%) NA 1 (3.3)
TNF-α blockade, n (%) NA 4 (13.3)
n, number; OA, osteoarthritis; RA, rheumatoid arthritis; SD, standard deviation; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; NA, not applicable.
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Tissue sections immunostained with anti-Sema3A antibody
were analyzed for 12 patients with OA and 12 patients with
RA. The total immunostaining intensity in the lining layer
was measured using a BZ-9000 microscope (Keyence,
Osaka, Japan) equipped with Dynamic Cell count software
BZ-H1C (Keyence). Immunostaining intensity per unit was
calculated as described previously [34].
Quantitative real-time polymerase chain reaction (qPCR)
Total RNA was extracted from synovial tissues using an
Illustra RNA spin Mini Kit (GE Healthcare, Bucking-
hamshire, UK) according to the manufacturer’s instruc-
tions. RNA was reversed transcribed into cDNA using a
PrimeScript RT Reagent Kit (Takara Bio, Ohtsu, Japan).
The cDNA synthesized from 1 μg of total RNA was used
as the template in each reaction. qPCR analysis was per-
formed using an Applied Biosystems 7900HT Fast Real-Table 2 Rooney’s inflammation scoring system for patients w
Histologic feature 0 1 2 3
Synoviocyte hyperplasiaa 1 2 3 4
Fibrosisb <10 <15 <20 <25
Proliferating blood vesselsc 0–3 4–5 6–7 8–9
Perivascular infiltrates of lymphocytesd <5 10 20 30
Focal aggregates of lymphocytese <11 15 20 25
Diffuse infiltrates of lymphocytesf 0 10 20 30
aA normal synoviocyte monolayer was scored as 0. The score was increased as the
tissue in the sublining layers were scored as 0. The score increased as the percenta
field (HPF) were scored as 0. The score increased as the number of vessels per HPF
as 0. The score increased as the percentage of vessels surrounded by lymphocytes
graded as mild = 2–4 cells in diameter, moderate = 5–7 cells in diameter, and seve
considered mild or severe, the original score was lowered by 1 point or raised by 1
exceeded 10 cells in diameter, were scored as 0. The score increased as the cell num
made of the percentage of cells per HPF that were lymphocytes. The score increasetime PCR system (Applied Biosystems LLC) based on
the TaqManW PCR manufacturer’s protocol. The assay was
performed in triplicate in optical 96-well reaction plates
covered with optical adhesive cover in a volume of 10 μl
containing 0.5 μl Taqman Gene Expression Assay 20X for
human Sema3A (assay ID Hs01085496_m1, GenBank ac-
cession number NM_006080, Applied Biosystems LLC),
VEGF-A (assay ID Hs00173626_m1, GenBank accession
number NG_008732, Applied Biosystems LLC), NRP1
(assay ID Hs00826128_m1, GenBank accession number
NM_003873; Applied Biosystems LLC) and β-actin (assay
ID 4326315E, GenBank accession number NM_001101;
Applied Biosystems LLC), 5 μl Taqman Fast Advanced
Master Mix 2X, 2 μl cDNA template and 2.5 μl RNase-free
water. The default ABI 7900HT amplification conditions
were 20 sec at 95°C, followed by 1 sec at 95°C and 20 sec at
60°C for 40 cycles. A standard curve, derived from known
serial dilutions of RA synovial tissue, was constructed toith rheumatoid arthritis
Score
4 5 6 7 8 9 10
5 6 7 8 9 10 >10
<30 <40 <50 <60 <70 <80 ≥80
10–11 12–13 14–15 16–17 18–19 20–22 >22
40 50 60 70 80 90 100
30 35 40 45 50 55 >55
40 50 60 70 80 90 100
synoviocyte lining layer increased in depth. bSections containing < 10% fibrous
ge of fibrosis in the section increased. cThree or fewer vessels per high power
increased. dWhen no lymphocytes were observed around vessels, it was scored
increased. Subsequently, the diameter of the perivascular lymphocytes was
re = 8–10 cells in diameter. Where the perivascular lymphocytes were
point, respectively. eAbsence of focal aggregates of lymphocytes, which
bers in the diameter of the focal aggregates increased. fAn estimate was
d as the percentage of lymphocytes increased.
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differences in primer efficiencies. The obtained data were
standardized using the reference gene, β-actin.
Double-staining Immunofluorescence
Synovial tissue specimens embedded in Optimum Cut-
ting Temperature compound (Sakura Finetek Japan,
Tokyo, Japan) were sectioned (5 μm thick). The sections
were then fixed in cold acetone for 5 min at 4°C and
rinsed in phosphate buffered saline (PBS). To eliminate
nonspecific protein binding, the samples were incubated
with 10% normal goat serum for 30 min at room
temperature. The samples were incubated with rabbit
anti-NRP1 polyclonal antibody (1:100; Santa Cruz Bio-
technology) and mouse anti-CD20 monoclonal antibody
(DAKO) overnight at 4°C. This was followed by incuba-
tion with Alexa 488-labeled goat anti-rabbit antibody
(Applied Biosystems LLC, Foster City, CA, USA) and
Alexa 594-labeled goat anti-mouse antibody (Applied
Biosystems LLC) for 40 min at 37°C. Finally, the sections
were mounted with aqueous mounting medium. The
distributions were analyzed by confocal microscopy
using a Zeiss LSM510 confocal laser microscope (Carl
Zeiss, Oberkochen, Germany).
Statistical analysis
Statistical analyses were performed using SPSS 11.0 for
Windows (SPSS Inc, Chicago, IL). The Mann–Whitney U-
test and Spearman’s rank correlation coefficient were used
to test the differences. A p value < 0.05 was considered sig-
nificant. We calculated a posterior power of this study
using G*Power (Faul, Erdfelder, Lang, & Buchner, 2007).
All statistical powers in this study were greater than 80%.
Results
Sema3A, VEGF165, NRP1 and CD3 expression in OA and
RA synovial tissues
To investigate the involvement of Sema3A in RA patho-
genesis, we performed immunohistochemical staining
for Sema3A, VEGF165 and NRP1 expression in serial
synovial serial sections from RA and OA patients. HE
staining demonstrated that synovial tissues from OA
patients contained two layers, the lining and sublining
layers (Figure 1A). Sema3A was mainly expressed in the
lining layer and a small number of inflammatory cells
were present in the sublining layer of OA samples
(Figure 1B). This immunoreactive signal was abolished
by the preincubation of anti-Sema3A antibody with the
antigen peptide (Figure 1C), confirming the specificity of
Sema3A immunostaining. In RA specimens, there was a
marked increase in synovial tissue thickness of the lining
layer caused by hyperplasia of synovial cells and numer-
ous infiltrating inflammatory cells in the sublining layer
(Figure 1D). The immunostaining signal of Sema3A inthe hyperplastic lining layer was lower in RA tissues com-
pared with OA samples (Figure 1E). Additionally, numer-
ous inflammatory cells in the sublining layer expressed
Sema3A. In OA and RA synovial tissues, VEGF165 was
expressed in the lining layer and in the inflammatory cells
of the sublining layer (Figure 1G, J). The VEGF165 expres-
sion density in the lining layer did not differ between RA
and OA samples. NRP1, the shared receptor for Sema3A
and VEGF165, was expressed in synovial cells of the lining
layer, along with inflammatory cells and vascular endothe-
lial cells in the sublining layer. The NRP1 expression dens-
ity in the lining layer of RA was not significantly different
to that of OA (Figure 1H, K). The localization of Sema3A,
VEGF165, and NRP1 almost overlapped, suggesting that
functional competition for Sema3A and VEGF165 may in-
fluence these cells. To evaluate the infiltration of immune
cells, sections were stained with anti-CD3 antibody, a
marker for T cells and anti-CD20 antibody, a marker for B
cells. While T cells (CD3) were sporadically localized in
the sublining layer of OA specimens, the number of T
cells was greater in RA synovial tissues (Figure 1I, L). B
cells were also sporadically localized in the sublining layer
of OA specimens and large numbers of B cells were
observed in the lymphoid follicles of RA synovial tissues
(Figure 1M, N). We quantified Sema3A-immunostaining
signal in the lining layer of RA and OA specimens.
Sema3A-immunostaining intensity per unit area of lining
layer was significantly less in RA patients compared with
OA (Figure 1O).
Expression of Sema3A, VEGF-A and NRP1 mRNA and
correlation with DAS28-CRP in RA
To confirm changes in Sema3A expression in RA, we
examined mRNA expression levels in OA and RA joint
specimens using qPCR analysis. To evaluate the expres-
sion levels of VEGF165 we used VEGF-A primers in the
qPCR experiments. Sema3A mRNA levels in synovial
tissue samples were significantly lower in RA (mean ex-
pression level 1.80) than in OA (mean expression level
6.68; p < 0.0001; Figure 2A). The mRNA expression of
VEGF-A or NRP1 was not significantly different between
RA and OA (Figure 2B, C). We also obtained similar results
with VEGF165 primer in preliminary study (Additional file
1: Figure S1A). We next examined the correlation of
Sema3A expression levels with DAS28-CRP, the disease
activity score for RA. A negative correlation was observed
between Sema3A expression levels and DAS28-CRP (R =
−0.409, p = 0.025; Figure 2D). This suggested that the
reduction of Sema3A expression might augment the
disease activity of RA. VEGF-A expression levels did
not significantly correlate with DAS28-CRP (R = 0.198,
p = 0.295; Figure 2E). We also found a negative correl-
ation between Sema3A/VEGF-A ratios and DAS28-CRP
(R = −0.449, p = 0.013; Figure 2F).
Figure 1 Histological/immunohistochemical analysis of Sema3A, NRP1, VEGF165 and CD3 in OA and RA synovial tissue. Representative
HE staining of OA (A) and RA (D) synovial tissues. OA synovial tissues contain lining (LL) and sublining (SL) layers. RA synovial tissues are marked
by the hyperplasia of synovial tissues in the lining layer and numerous infiltrated inflammatory cells (IC) in the sublining layer. Sema3A expression
was detected in the lining layer and inflammatory cells in the sublining layer of OA (B) and RA (E) synovial tissues. The density of the Sema3A
signal in the lining layer was lower in RA than OA. Peptide-neutralized anti-Sema3A antibodies did not stain tissue sections from OA (C) and RA
(F). NRP1 and VEGF165 localized to the same areas as Sema3A in OA. VEGF165 expression in the lining layer in RA tissues was similar with OA
(G, J). The NRP1 expression level in the lining layer of RA was similar to OA (H, K). T cells (CD3) and B cells (CD20) were detected among
inflammatory cells in the sublining layer of OA and RA synovial tissues (I, L, M, N). The numbers of T cells and B cells were higher in RA synovial
tissues compared with OA. Sections were counterstained with hematoxylin. Scale bars = 50 μm in the whole image view and 25 μm in the
magnified view. Immunostaining of lining layer Sema3A was significantly decreased in RA (n = 12) synovial tissues compared with OA (n = 12)
subjects (O). Results are presented as relative values compared with OA subjects. The box plots demonstrate the 10th and 90th percentile
(whiskers), the 25th and 75th percentile, and the median. P values were obtained using the Mann–Whitney U-test.
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Figure 2 Expression of Sema3A, VEGF-A and NRP1 mRNA in synovial tissues. Expression levels of Sema3A, VEGF-A and NRP1 mRNA were
measured using real-time PCR. The mRNA levels were normalized to the expression of β-actin. The box plots demonstrate the 10th and 90th
percentile (whiskers), the 25th and 75th percentile, and the median. Sema3A mRNA levels were significantly decreased in RA (n = 30) synovial
tissues compared with OA (n = 23) (A). VEGF-A and NRP1 mRNA levels were not significantly altered (B, C). Correlation of Sema3A mRNA levels
and DAS28-CRP (D); VEGF-A mRNA levels and DAS28-CRP (E); and Sema3A/VEGF-A mRNA levels and DAS28-CRP (F). P values were obtained using
the Mann–Whitney U-test. were examined using Spearman’s rank correlation coefficient.
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features in RA synovial tissues
To confirm the inverse correlation of Sema3A mRNA
expression levels and RA disease activity, we compared
the relative Sema3A mRNA expression levels with histo-
logical parameters of RA synovial tissues. This included
the degree of synovial hyperplasia, fibrosis, number of
blood vessels present, perivascular infiltrates of lympho-
cytes, focal aggregates of lymphocytes and diffuse infil-
trates of lymphocytes. No significant correlation
between Sema3A expression and synovial hyperplasia, fi-
brosis or the number of blood vessels was observed
(Figure 3A–C). In contrast, perivascular infiltrates of
lymphocytes, focal aggregates of lymphocytes and diffuse
infiltrates of lymphocytes significantly correlated with
Sema3A mRNA expression levels (R = −0.506, p = 0.004;
R = −0.501, p = 0.005; R = −0.536, p=0.002 respectively;
Figure 3D–F). These results indicated that Sema3A
mRNA reduction was mainly associated with immune
reactions in the synovial tissue from RA patients.
Expression of NRP1 in CD20-positive B cells in
lymphocyte aggregates
Histological scores and Sema3A expression levels
revealed that a decrease in Sema3A augmented focal
aggregates of lymphocytes. To examine the cell types ofNRP1-positive inflammatory cells, we stained sequential
tissue sections with markers for T cells (CD3) and B cells
(CD20). NRP1 was abundantly expressed in the inflam-
matory cells of lymphoid follicles (Figure 4A). In RA
synovium, T cells, B cells and dendritic cells [35] can be
arranged in sophisticated organizations that resemble
the microstructures usually formed in secondary lymph-
oid organs. Interestingly, NRP1-expressing dendritic
cells also exist in the lymphoid follicle/lymphocyte focal
aggregates. Immunohistochemical staining of sequential
slices from the lymphoid follicles showed that NRP1-
positive cells also expressed CD3 or CD20 (Figure 4B, C).
Since lymphoid follicles were mainly composed of B cells
[36], we also performed double immunofluorescence
staining of NRP1 and CD20. The NRP1 positive signal
colocalized with the CD20 positive signal in the inflamma-
tory cells of lymphocyte aggregates (Figure 4D-F).
Discussion
It has been suggested that abnormalities of the immune
system play an important role in the pathogenesis of
chronic inflammatory conditions such as RA. This study
revealed Sema3A expression levels significantly corre-
lated with the histological score of perivascular infiltrates
of lymphocytes, focal aggregates of lymphocytes and dif-
fuse infiltrates of lymphocytes. Sema3A is involved in
Figure 3 Expression levels of Sema3A mRNA correlate with histological features in RA synovial tissues. Correlations between Sema3A
mRNA expression levels and histological parameters of RA synovial tissues were assessed. Histological parameters were scored separately on a
scale of 0–10 according to Rooney’s inflammation scoring system. Correlation of Sema3A mRNA levels and synoviocyte hyperplasia (A); Sema3A
mRNA levels and fibrosis (B); Sema3A mRNA levels and proliferating blood vessels (C); Sema3A mRNA levels and perivascular infiltrates of
lymphocytes (D); Sema3A mRNA levels and focal aggregates of lymphocytes (E); and Sema3A mRNA levels and diffuse infiltrates of lymphocytes
(F). Correlations were examined using Spearman’s rank correlation coefficient.
Figure 4 Immunohistochemical and double immunofluorescence staining of lymphocyte aggregates. NRP1 was abundantly expressed by
inflammatory cells of lymphocytes aggregates (A). Immunohistochemical staining of sequential sections showed that NRP1-positive cells in
lymphocytes aggregates also expressed CD3 (B) or CD20 (C). Micrographs show the double immunofluorescence detection of NRP1 (D, green)
and CD20 (E, red) with the merged images (F). The NRP1 positive signal colocalized with the CD20 positive signal in the inflammatory cells of
lymphocyte aggregates. A–C, scale bars = 50 μm; D–F, scale bars = 10 μm.
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in several autoimmune diseases [29,37,38]. The NRP1
and PlexinA complex mediates Sema3A signaling in the
immune system [39]. NRP1 is expressed by regulatory T
cells, a subset of T cells [40] and PlexinA4 regulates T
cell proliferation and activation through inhibition of the
actin-cytoskeleton rearrangement and T cell receptor
polarization [9]. Recently, it was reported that Sema3A
promotes regulatory T cells by enhancing IL-10 produc-
tion [14]. Regulatory T cells play an important role in
maintaining immunological self-tolerance by suppressing
autoreactive T cells [41]. Immunohistochemical staining
in the current study revealed that Sema3A is expressed
in the lining layer. Thus, in OA joints, secreted Sema3A
from the lining layer may enhance regulatory T cell func-
tions to suppress autoimmune responses in the sublining
layer. In RA, the reduction of Sema3A may abrogate the
functions of regulatory T cells, thus allowing the infiltra-
tion and focal aggregation of autoreactive lymphocytes in
the sublining layer. Further investigation of the correlation
between Sema3A and IL-10 expression levels may in-
crease our understanding of their roles in RA.
Catalano reported synovial tissues derived from healthy
controls, OA and RA patients exhibited no significant dif-
ferences although the relative Sema3A expression was
lowest in RA samples [14]. This discrepancy might be
explained by the difference in sampling numbers, which
can influence statistical power, and/or by different qPCR
methods used. We quantified Sema3A mRNA expression
in a larger number of RA patients (n = 30) and OA
patients (n = 23), whereas Catalano used relatively small
numbers of RA (n = 10), OA (n = 10) patients and healthy
controls (n = 5). For qPCR, we used the standard curve
method for relative quantification, whereas Catalano used
a comparative Ct method.
Sequential immunohistochemical staining revealed that B
cells were observed mainly in the lymphoid follicles, con-
sistent with a previous report [36]. Here we observed that
B cells in the follicles expressed NRP1 (Figure 4). Vadasz
et al. recently suggested that Sema3A can modulate the
autoimmune properties of B cells in SLE [13]. Thus,
Sema3A may exert similar functions in NRP1-positive B
cells from RA synovial tissues. Vadasz et al. also reported
Sema3A serum levels were significantly lower in SLE
patients (p < 0.0001) and RA patients (p = 0.047) compared
with healthy controls [13]. Since Sema3A is a secreted sol-
uble protein and can enter the systemic circulation [16,42],
lower Sema3A serum levels in RA patients may reflect its
reduced expression in knee joints and/or other organs.
Additional investigations to quantify the serum levels of
Sema3A from OA and RA patients may contribute to fur-
ther elucidation of pathogenesis of the disease.
It is unclear which factors regulate Sema3A expression
in synovial tissues. However, Fukamachi et al. reportedthat the presence of calcium and histamine could modu-
late Sema3A expression levels in human keratinocytes and
fibroblasts [43]. Since histamine is associated with RA
pathogenesis [44,45], it may be responsible for the
decreased Sema3A levels observed in RA synovial tissues.
We found that mRNA expression of VEGF-A was not
significantly altered in OA and RA synovial tissues.
Hashimoto et al. reported staining intensity for VEGF
expression did not differ between RA and OA synovial
lining [46] and Lowin et al. reported that VEGF165 ex-
pression did not differ in the chronically inflamed tissue
of RA patients and OA patients [47]. In contrast, several
reports showed altered expression of VEGF in RA. Lee
et al. observed significantly higher levels of VEGF pro-
tein in RA compared with OA synovial fluid and serum
[48]. Kurosawa et al. observed significant correlations of
serum VEGF levels with DAS28-CRP scores [24]. The
elevation of VEGF protein in RA synovial fluid and
serum may explain the higher total number of VEGF-
producing cells in the region [46]. Indeed, our study
showed no signification correlation between VEGF-A ex-
pression levels and DAS28-CRP scores (Figure 2), but
there was a marked increase of synovial tissue thickness
of the lining layer in RA (Figure 1). Thus, VEGF levels
in RA serum may be increased as previously reported
[24]. In an earlier study, Ikeda et al. reported VEGF165
was expressed in 41% of RA samples (17 patients) but not
in OA samples (8 patients) using reverse transcription-
PCR [49]. They also found NRP1 was up-regulated in RA
synovial tissues. However, we did not observe significant
alterations of VEGF-A (Figure 2B) or NRP1 (Figure 2C)
between OA and RA specimens. Kim et al. reported that
NRP1 expression was similar in OA and RA using immu-
nohistochemical analyses [50]. These discrepancies might
be explained by the difference in sampling numbers, dis-
ease duration of the populations studied, extent of inflam-
mation, use of anti-rheumatoid drugs, and/or by different
methods for analysis of NRP1 expression levels. Additional
investigations in a large sample considering several differ-
ent conditions are required to clarify these discrepancies.
Although Sema3A inhibits endothelial formation and
angiogenesis due to competition with VEGF165 [51], this
study did not identify a significant correlation between
Sema3A mRNA expression levels and blood vessel dens-
ity in RA synovial tissues. This suggests that angiogen-
esis in RA lesions may be regulated by other mediators,
such as placenta growth factor 1, IL-2 and hepatocyte
growth factor [47,52].
The imbalance between Sema3A and VEGF may also
affect the etiology of RA. Although VEGF-A expression
levels did not exhibit a significant correlation with DAS28-
CRP scores, the Sema3A/VEGF-A mRNA ratios demon-
strated a relationship with the RA clinical score. Several
studies have demonstrated that anti-NRP1 peptides
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VEGF165-induced synovial cells, which contribute to cartil-
age destruction in RA [50,53]. VEGF165 also increased the
production of cytokines by human peripheral blood mono-
nuclear cells [54]. Sema3A may inhibit the action of
VEGF165 on synovial cells and inflammatory cells in a com-
petitive manner.
Innervation is important in the pathogenesis of arth-
ritis. Primary afferent sensory nerve fibers are proinflam-
matory, whereas sympathetic nerve fibers are anti-
inflammatory [55]. In RA synovial tissues, numbers of
sympathetic nerve fibers decreased while sensory nerves
increased when compared with OA [56]. The loss of
sympathetic nerve fibers in RA may be caused by
increased Sema3C and its soluble receptor NRP2 [6,55].
However, the mechanism of increased sensory nerve
fibers in RA synovial tissues is not fully understood.
Decreased Sema3A expression in RA may facilitate the
increase of sensory nerves over sympathetic nerves in
inflamed RA synovium [55].
Several limitations of our study should be addressed.
First, this study population may be influenced by envir-
onmental factors as well as genetic factors. Second,
patients enrolled in our study were in the advanced
stages of RA disease (mean duration 16.3 years). Thus,
our data do not reflect the pathogenesis of RA during
the early stages. Third, anti-rheumatoid drugs may
alter the expression level of Sema3A and other mole-
cules. In this study 12 patients (40%) received metho-
trexate (MTX) (mean prednisolone daily dose 2.9 mg), 4
patients (13.3%) received TNF-α blockade (3 patients in
combination with MTX, 1 patient in combination with
sulfasalazine, mean prednisolone daily dose 3.6 mg), 11
patients received Disease Modifying Antirheumatic
Drugs (DMARDs) without MTX (mean prednisolone
daily dose 1.6 mg), and 3 patients received prednisolone
alone (daily dose 6.2 mg). Although there was no statisti-
cally significant difference in Sema3A expression,
DAS28-CRP, or Rooney’s inflammation score between
the MTX–treated group and other groups (data not
shown), we cannot rule out the possibility of altered
Sema3A expression by anti-rheumatoid drugs, because
each group sample size is small in this study.
Conclusions
This study demonstrated that Sema3A expression levels
and the disease activity score in patients with RA nega-
tively correlated with histological parameters in RA syn-
ovial tissues. This suggests that Sema3A may have a
suppressive effect on the pathological severity of RA.
Further elucidation of the role of Sema3A in joints may
elucidate the biological and pathological functions of
Sema3A and allow the development of new strategies for
the treatment of RA.Additional file
Additional file 1: Expression of VEGF165 mRNA in synovial tissues:
preliminary study. Expression levels of VEGF165 mRNA were measured
by real-time PCR. The mRNA levels were normalized to the expression of
β-actin. The box plots demonstrate the 10th and 90th percentile
(whiskers), the 25th and 75th percentile, and the median. VEGF165 mRNA
levels were not significantly altered in RA (n = 25) synovial tissues
compared with OA (n = 17) (A). VEGF165 expression levels did not
significantly correlate with DAS28-CRP (B).
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